“It certainly seems that we're moving into medical management of advanced diseases,” says J. Christopher Webster, MD, FACS.
In this video, J. Christopher Webster, MD, FACS, makes his predictions for future advancements in urology over the next several years. Webster is a urologist with Colorado Urology in Westminster. He was interviewed at the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Medicare’s G2211 and thoughts on how to best use it in urology
May 1st 2024"We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and we have had some experience using the code now that it is active and been able to observe some of the initial payment processing by the payer," write Jonathan Rubenstein, MD, and Mark Painter.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.